MS
CRDF icon

Maven Securities’s Cardiff Oncology CRDF Stock Holding History

Maven Securities’s Portfolio CRDF Stock Details CRDF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-5,484
Closed -$51K – 1103
2021
Q1 		$51K Buy
+5,484
New +$66.6K ﹤0.01% 1084
2020
Q4 		– Sell
-60,000
Closed -$853K – 615
2020
Q3 		$853K Buy
+60,000
New +$396K 0.07% 272

Other funds holding CRDF

EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CC
Caxton Corporation Princeton, New Jersey $1.85M AUM 176.16% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
CA
Corriente Advisors Fort Worth, Texas $9.53M AUM 805.26% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Maven Securities's CRDF Position: Q2 2021 in Review

Maven Securities sold out of Cardiff Oncology (CRDF) in Q2 2021, closing a stake of 5,484 shares — an estimated $51K sold.

Maven Securities first reported a position in CRDF in Q3 2020 and held it in 2 quarters. The position peaked at $853K in Q3 2020. 90 funds tracked by Wall St. Rank hold CRDF as of Q2 2021.

  • Maven Securities reported no remaining Cardiff Oncology position as of Q2 2021 after selling out during the quarter.
  • Maven Securities sold 5,484 Cardiff Oncology shares in Q2 2021, an estimated $51K.
  • Maven Securities first reported a position in Cardiff Oncology in Q3 2020 and held it in 2 quarters.
  • Maven Securities's Cardiff Oncology position peaked at $853K in Q3 2020.
  • 90 funds tracked by Wall St. Rank held Cardiff Oncology as of Q2 2021.

Based on Maven Securities's 13F filing for Q2 2021, filed 16 Aug 2021.